
Are you looking for ASX shares to buy after this month’s market weakness?
Well, if you are, let’s see what analysts are saying about the popular shares in this article, courtesy of The Bull.
Are they buys, holds, or sells? Let’s find out:
Northern Star Resources Ltd (ASX: NST)
This gold miner’s shares have been named as a buy by the team at MPC Markets.
It highlights that while it owns one of the best gold assets in the world, it has been disappointed with its operational performance. It explains:
The gold company has been punished for downgrading gold production. Mechanical and equipment issues at its flagship Kalgoorlie operation have been frustrating, and the market has lost patience. However, Northern Star still owns one of the best gold assets in the world and its long term reserve base is intact.
The conflict in Iran has also generated indiscriminate selling in gold miners that history tends to show as a buying opportunity. Operational problems are temporary and we expect the gold price to improve moving forward.
Telix Pharmaceuticals Ltd (ASX: TLX)
MPC Markets is a lot more positive on the radiopharmaceuticals company and has named it as a buy this week.
It is feeling optimistic that Telix may finally be granted FDA approval for Pixclara this year. It commented:
The company’s prostate imaging agent is generating strong sales in the United States. The near term story is about brain cancer imaging. The company recently re-submitted its drug application to the US Food and Drug Administration (FDA) for Pixclara, an imaging agent for a particularly aggressive form of brain cancer.
The FDA has given it priority status, and Telix has gone through a formal meeting to address every question raised in its previous application. In our view, a re-submission isn’t a setback, but the last step before approval. We believe the market isn’t pricing in the benefits of a potentially successful FDA outcome.
Virgin Australia Holdings Ltd (ASX: VGN)
Over at Catapult Wealth, it has put a hold rating on this airline operator’s shares.
While it was pleased with its strong performance during the first half, it is concerned about rising expenses. It explains:
The Australian airline delivered a strong result in the first half of fiscal year 2026, with underlying earnings before interest and tax increasing by 11.7 per cent to $490 million. Revenue per available seat kilometre (RASK) was up 6.4 per cent. The group’s transformation program delivered more than $200 million in gross benefits.
The company has now exhausted tax losses and will begin paying tax, with franking credits at $94 million. While demand and yields remain supportive, rising expenses suggest a balanced hold stance.
The post Buy, hold, sell: Northern Star, Telix, and Virgin Australia shares appeared first on The Motley Fool Australia.
Should you invest $1,000 in Northern Star Resources Limited right now?
Before you buy Northern Star Resources Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Northern Star Resources Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Here are the top 10 ASX 200 shares today
- These are the 10 most shorted ASX shares
- 5 things to watch on the ASX 200 on Monday
- ASX 200 mining shares rebound after March sell-off creates opportunities
- Here are the top 10 ASX 200 shares today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.








